|
Follow the links below to find summaries of systematic reviews of the evidence for the effectiveness of treatments for Alzheimer's Disease.
Reviewed July 2009
Printer friendly page
| Results 1 to 20 displayed. |
|
1
2
|
| Title: |
Statins for the prevention of dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Evidence accumulating from biological and epidemiological studies suggest that high levels of serum cholesterol may promote the pathological processes that lead to Alzheimer's disease. Lowering cholesterol in experimental animal models slows the express...
|
| Date: |
Nov 2008
|
| Title: |
Memantine for dementia in people with Down syndrome
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Memantine is thought to improve cognitive function and slow the decline of AD over time.The effects of memantine on AD are reported to be beneficial for people with moderate to severe AD in the general population, However, people with DS tend to present...
|
| Date: |
Oct 2008
|
| Title: |
Rivastigmine for dementia in people with Down syndrome
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
The drug rivastigmine has been reported to have benefits for people with mild to moderate Alzheimer's disease who do not have Down syndrome. However, people with DS tend to present with AD at a much younger age than the general population as well as bei...
|
| Date: |
Oct 2008
|
| Title: |
Galantamine for dementia in people with Down syndrome
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
The drug galantamine has been reported to have benefits for people with mild to moderate Alzheimer's disease who do not have Down syndrome. However, people with DS tend to present with AD at a much younger age than the general population as well as bein...
|
| Date: |
Oct 2008
|
| Title: |
Donepezil for dementia in people with Down syndrome
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Donepezil is a drug which is thought to discourage the breakdown of acetylcholine, which is a neurotransmitter in the brain that is important to how memory functions. Acetylcholine is lacking in people with Alzheimer's disease (AD). The drug donepezil h...
|
| Date: |
Oct 2008
|
| Title: |
Rivastigmine for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Alzheimer's disease (AD) is the commonest cause of dementia affecting older people, and is associated with loss of cholinergic neurons in parts of the brain subserving aspects of memory. Acetylcholinesterase inhibitors, such as rivastigmine, delay the b...
|
| Date: |
Sep 2008
|
| Title: |
Alpha lipoic acid for dementia
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Alpha lipoic acid (ALA) is one of a number of potent antioxidants for which a potential therapeutic role in dementia has been postulated. This suggestion arises from the possibility that oxidative and inflammatory processes contribute to the neurodegene...
|
| Date: |
Jul 2008
|
| Title: |
Physostigmine for dementia due to Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Physostigmine is an acetylcholinesterase inhibitor; it works by obstructing the enzyme responsible for ACh destruction in the synaptic cleft. Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or wi...
|
| Date: |
Jun 2008
|
| Title: |
Velnacrine for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts ...
|
| Date: |
May 2008
|
| Title: |
Ibuprofen for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
There is increasing interest in non-steroidal antiinflammatory drugs (NSAIDs) for the treatment of Alzheimer's disease (AD). Extensive epidemiological surveys have suggested a lower prevalence of cognitive impairment in patients receiving long term trea...
|
| Date: |
May 2008
|
| Title: |
Thiamine for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Preclinical and laboratory studies show an effect of thiamine on the release and breakdown of acetylcholine. Some intellectual functions, including attention and memory, are influenced by neurons which release acetylcholine. Cholinergic function is impa...
|
| Date: |
May 2008
|
| Title: |
Indomethacin for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Extensive evidence implicates inflammatory processes in the pathogenesis of Alzheimer's disease. Non-steroidal anti-inflammatory drugs such as indomethacin have been proposed for the treatment of patients with Alzheimer's disease. Only one study met cri...
|
| Date: |
May 2008
|
| Title: |
D-cycloserine for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
D-cycloserine is a broad-spectrum antibiotic formerly used at high doses (500-1000 mg / day) for the treatment of tuberculosis (TB). It has been suggested that D-cycloserine might improve memory and other cognitive processes through its desired effects...
|
| Date: |
May 2008
|
| Title: |
Selegiline for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Despite its initial promise, i.e. the potential neuroprotective properties, and its role in the treatment of Parkinson's disease, selegiline for Alzheimer's disease has proved disappointing. Although there is no evidence of a significant adverse event p...
|
| Date: |
Apr 2008
|
| Title: |
Piracetam for dementia or cognitive impairment
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Piracetam was one of the first drugs used for dementia and comes from the class of drugs called nootropics, whose putative actions are still poorly defined. Most of the trials of piracetam were undertaken many years ago and did not use methods which wou...
|
| Date: |
Apr 2008
|
| Title: |
Metrifonate for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Metrifonate cannot be recommended for treatment for Alzheimer's disease...
|
| Date: |
Feb 2008
|
| Title: |
Huperzine A for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Huperzine A is derived from Chinese club moss Huperzia serrata, and is described as having several properties which may be beneficial for AD. This review looked for randomized trials comparing Huperzine A with control in patients with AD. Six trials wer...
|
| Date: |
Feb 2008
|
| Title: |
Nicotine for Alzheimer's disease
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Nicotine has been related to recovery of memory in humans and animal models and some observational studies have been compatible with a protective effect of nicotine inhalation against Alzheimer's disease. At present, there is great controversy over this...
|
| Date: |
Jan 2008
|
| Title: |
Vitamin E for Alzheimer's disease and mild cognitive impairment
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Vitamin E is a dietary compound with antioxidant properties involved in scavenging free radicals. Laboratory and animal studies have pointed towards a possible role for Vitamin E in the prevention and management of cognitive impairment. To date only one...
|
| Date: |
Jan 2007
|
| Results 1 to 20 displayed. |
|
1
2
|
|
